DOI: 10.1182/bloodadvances.2023010461 ISSN:
CD19-CAR T-Cell Therapy Demonstrates Activity Against Extramedullary Disease in Pediatric Patients with B-ALL
Rebecca Epperly, Barry L. Shulkin, Asim K. Bag, Cheng Cheng, Hiroto Inaba, John T. Lucas, Swati Naik, Brandon M. Triplett, Stephen Gottschalk, Aimee C. Talleur- Hematology
Key Points
There is a high burden of extramedullary disease in pediatric patients with relapsed/refractory B-ALL prior to CD19-CAR T cell therapy CD19-CAR T cells can have activity at extramedullary B-ALL sites, but overall response is less robust than for bone marrow disease